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Patch clamp experiments were used to characterize the effect of dexamethasone on calcium currents in A7r5 cells. Pretreatment for 48 h with 200 
nM dexamethasone did not affect the single channel conductance, the voltage dependence of channel opening, or the voltage-dependent i activation 
of L-type channels. However, dexamethasone caused an approximately 2-fold increase in the amplitude of L-type calcium currents in 5 out of 9 
experiments, uggesting an increase in the number of active channels. The effect of dexamethasone appeared to be greatest on batches of cells with 
low control current density. The amplitude of T-type calcium current was not affected by dexamethasone. 
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1. INTRODUCTION 
Hypertension often accompanies Cushing’s syn- 
drome, which is caused by elevated levels of plasma 
glucocorticoids [l]. An anomalous reactivity to vascular 
agonists seems to underlie this hypertensive state since, 
in patients and animal models with this syndrome, 
lower doses of norepinephrine and angiotensin II are 
required to induce pressor responses [2]. 
Strong evidence suggests that the vascular tone is 
mediated by an steady calcium influx through L-type 
calcium channels [3]. Modulation of calcium channels 
by membrane potential or second messengers would 
affect calcium entry, and in turn, vascular peripheral 
resistance. This raises the possibility that the increased 
vascular resistance in Cushing’s syndrome results from 
a glucocorticoid-induced increase in activity of L-type 
calcium channels. In support of this hypothesis, dexa- 
methasone treatment increased both nefedipine-sensi- 
tive Ca45 influx and the number of high affinity binding 
sites for dihydropyridines, in the A7r5 vascular smooth 
muscle cell line [4]. An increase in channel activity could 
result from an increase in (a) the probability that a 
channel is open, (b) the single channel current, or (c) the 
number of functional channels. Binding of dihy- 
dropyridines (DHPs) and Ca45 flux experiments cannot 
distinguish between these possibilities. Moreover, inter- 
pretation of the results is complicated by the lack of a 
direct relationship between the number of DHP binding 
sites and the number of functional channels [5,6], and 
the voltage dependence of DHP binding [7]. Since 
*Corresponding author. Fax: (1) (216) 368 5586. 
Published by Elsevier Science Publishers B. V 13 
changes in activity of voltage-dependent calcium chan- 
nels could also be secondary to changes in membrane 
potential, measurements under voltage clamp conditions 
are necessary to understand mechanistically the basis of 
dexamethasone effects on L-type Ca” channels. 
We have previously characterized the kinetics of acti- 
vation and inactivation of L-type calcium channels in 
the A7r5 cell line using the patch-clamp technique [5,8- 
lo]. Using the same methods, we have studied the effects 
of dexamethasone on calcium channel currents in this 
cell line. We find that dexamethasone does not affect the 
single channel conductance, the voltage dependence of 
activation, or inactivation of this channel. Instead, our 
results suggest hat dexamethasone increases the num- 
ber of active L-type calcium channels. 
2. MATERIALS AND METHODS 
2.1. Cell preparation 
The A7r5 cell line, originally derived from embryonic rat aorta, was 
obtained from the American Type Culture Collection (ATCC). The 
two different batches of cells used were obtained from the ATCC in 
3188 and 8192. Cells were grown as previously described [5]. Before the 
experiments, confluent cell layers were dispersed with trypsin, resus- 
pended in Dulbecco’s Modified Eagle’s Medium containing 0.5% (by 
vol.) fetal calf serum, and plated on 35 mm dishes. After attachment 
of the cells to the dish, cytochalasin-D (1 @ml) was added to maintain 
a rounded morphology [5]. Experiments were carried out at room 
temperature (- 22°C). 
2.2. Chemicals 
Dexamethasone (9a-fluoro-16a-methylprednisolone) (lots no. 
129F-01295 and 62H0202; HEPES (N-[2-hydroxyethyl]-piperazine- 
K-2-ethanesulfonic acid); NMG (N-methylglucamine); EGTA (ethyl- 
eneglycol-bis-@-aminoethyl ether) N,N,N’,N’-tetraacetic acid), TEA- 
Cl (tetraethylammonium chloride), BaCI,, K glutamate, and MgATP 
were obtained from Sigma Chemical Co. (St. Louis, MO). CsCl and 
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CsOH were obtained from Fisher (Pittsburgh, PA). (+)202-791 was 
a gift from Drs. D. Rdmer and E. Rissi (Sandoz, Base], Switzerland). 
2.3. Steroid treatment 
Confluent cultures were exposed to 200 nM dexamethasone in 10% 
(by vol.) fetal calf serum for 48 h. 200 nM dexamethasone was shown 
to induce a maximal stimulation of Ca4’ uptake in A7r5 cells after 
one day of exposure [4]. Where noted, before the addition of dexa- 
methasone, fetal calf serum was treated with charcoal in order to 
remove contaminant cortisol [4]. Dexamethasone was added from a 
20 mM stock solution dissolved in ethanol. The controls were cells 
treated with 10% fetal calf serum plus vehicle. 
2.4. Voltage clamp measurements 
Voltage clamp was established in the whole-cell and cell-attached 
configurations [Ill using an Axopatch-1B patch clamp amplifier 
(Axon Instruments, Foster City, CA). Voltage commands were given 
and data were obtained using a Labmaster A-D converter with 
pClamp software (Axon Instruments) on an IBM AT-compatible mi- 
crocomputer. 
In whole-cell experiments, electrodes had series resistances of 2-5 
MR. The standard extracellular solution contained (in mM): BaCl, 15, 
TEA-Cl 121, glucose 10, NMG-HEPES 10, pH 7.4. The standard 
intracellular solution contained (in mM): CsCl 130, MgATP 5, Cs- 
EGTA 10, Cs-HEPES 10, pH 7.2. During the whole cell recording, the 
capacity transient induced by a -10 mV step pulse was canceled by 
electronic compensation. The cell capacitance was read from the 
‘whole cell capacitance’ dial on the Axopatch, following cancellation 
of the capacity transient. For the cell-attached configuration, elec- 
trodes of - 5 MR were made with borosilicate glass (World Precision 
Instruments, New Haven, CT) and coated with silicone rubber. The 
pipette solution contained (in mM) BaCl, 110 mM, NMG-HEPES 10 
mM, pH 7.3. After seals were formed in a physiological salt solution, 
the cell membrane potential was zeroed with a bath solution contain- 
ing (in mM): KGluconate 140, NMG-EGTA 5, NMG-HEPES 10, pH 
7.3. 1 ,uM (+)202-791 was added to increase the resolution of single 
channel measurements. 
3. RESULTS 
Fig. 1A compares peak current densities in control vs. 
cells treated with 200 nM dexamethasone for 48 h. This 
represents a summary of all the experiments conducted 
using 9 different batches of cells. Each point represents 
the mean value from one cell preparation. Data points 
above the dashed line reflect up-regulation of calcium 
currents by dexamethasone, which was observed in 5 of 
9 experiments. The effect on current density did not 
depend in an obvious way on the batch of cells used 
(indicated in Fig. 1 by different symbols). We attempted 
to decrease the experimental variability by pretreating 
the fetal calf serum with charcoal to remove steroids [4], 
but cell-cell and batch-batch variability did not decrease 
(open circles). The variability of the effect of dexa- 
methasone could be partially accounted for by a varia- 
tion in the basal level of calcium channel activity in the 
different experiments. This is shown in Fig. lB, where 
the ratio of current densities is plotted as a function of 
the control current density. Four of five positive exper- 
iments had control current densities equal to or smaller 
than 10 pA/pF, and four of five experiments with such 
low current densities produced a positive result. 
To understand the mechanism underlying the in- 
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Fig. 1. The effect of dexamethasone on calcium current density. (A) 
Correlation between mean current levels in control and dexa- 
methasone-treated cells. The numbers near each symbol indicate the 
number of dexamethasone-treated cells/number of control cells 
studied in each experiment. Values are mean + S.E.; we note that 
S.E. values calculated for n = 2-3 may not be accurate. (B) Correlation 
between enhancement of current by dexamethasone (dex./control 
ratio) and the control current levels. For the dex./control 
ratio, the fractional SE (lSE = SE/mean) was calculated as 
fS&exlcontro, = @SE’,,, + fSE’,,,,,i)“. 
crease in current induced by dexamethasone in cells 
with low basal current levels, current-to-voltage rela- 
tionships were examined for the three batches of cells 
where the current increased by a factor of 2.0 or larger 
(Fig. 2A). In A7r5 cells, with Ba*’ as the charge carrier, 
L-type calcium currents activate above -30 mV, reach 
a peak near +lO mV, and then decrease in amplitude as 
the driving force on Ba2’ decreases [5,8,12,13]. The 
shape of the current-voltage relation and the extrapo- 
lated reversal potential were not affected by dexameth- 
asone (Fig. 2A). This suggests that the voltage depend- 
ence of channel gating and the permeation characteris- 
tics of the calcium channels were identical in control and 
treated cells. No change in cell capacitance was ob- 
served (Fig. 2, legend). Fig. 2B shows current-voltage 
relationships for batches of cells where no change in 
current was evident. 
Several lines of evidence indicate that the effect of 
dexamethasone is on L-type calcium currents, as op- 
posed to the T-type currents that are occasionally ob- 
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served in A7r5 cells [12]. First, the potentiated currents 
were blocked by 1 ,uM nifedipine or 100 PM Cd’+, 
whereas T-current is resistant to 1 PM nifedipine (not 
shown). Second, normal voltage dependence was ob- 
served for dexamethasone-treated cells when the mem- 
brane potential was held at -40 mV, which inactivates 
the rapid transient component of current (not shown). 
Third, dexamethasone had no effect at relatively nega- 
tive voltages (-40 to -30 mV) (Fig. 2A), where T-type 
calcium channels can make a substantial contribution 
to the whole-cell current. Fourth, and most directly, the 
amount of current inactivating during a 70 ms depolar- 
ization to -20 mV (Fig. 2C) was unaffected by dexa- 
methasone: the rapidly inactivating component was 
-0.36 f 0.05 pA/pF in control (mean f S.E., n = 6), 
compared to -0.35 + 0.07 pA/pF in dexamethasone 
(n = 7). Measurement of T-current in this way is sup- 
ported by the observation that L-currents in Ba” show 
little inactivation during pulses as long as 300 ms at -20 
mV [8], while T-currents inactivate with a half time of 
14 ms [12]. The sustained current could be contami- 
nated slightly by T-current, which may not inactivate 
fully at negative membrane potentials [14]. However, 
since dexamethasone does not affect the transient com- 
ponent, it is unlikely that the hormone has a selective 
effect on a sustained component of T-current. 
We also examined inactivation of L-type currents in 
control and dexamethasone-treated cells, using a dou- 
ble-pulse protocol [ 151. Inactivation, produced during 
long prepulses (330 ms) to various voltages, was assayed 
by test pulses to +lO mV, from a holding potential of 
-40 mV. Using this protocol, inactivation increases 
monotonically with depolarization, and reaches a 
steady value at potentials more positive than +20 mV 
[8]. This voltage dependence was not modified by dexa- 
methasone (not shown). 
We further investigated the effect of dexamethasone 
at the single-channel level, using cell-attached patch 
clamp recording. Using (+)202-791 to enhance channel 
activity, L-type channels were observed in 7 of 20 (35%) 
patches from control cells, and 10 of 19 (53%) patches 
from dexamethasone-treated cells. This difference was 
not statistically significant (2 x 2 contingency table, 
[16]), although the data are consistent with a higher 
channel density per patch in dexamethasone treated 
cells (Fig. 3A). Since in these experiments we did not 
distinguish between batches of cells with high or low 
basal channel activity, the effect of dexamethasone may 
be underestimated. Dexamethasone did not affect the 
slope conductance of the channels (26 pS, Fig. 3B), 
consistent with the evidence from whole-cell recording 
(Fig. 2A) that calcium channel permeation is not af- 
fected. 
4. DISCUSSION 
From their experiments using Ca4’ flux and DHP 
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Fig. 2. Effects of dexamethasone on T- and L-type calcium currents. 
Current-to-voltage relationships from experiments where dexa- 
methasone increased L-type calcium currents (A) and where no effect 
was noticed (B). The three batches of cells where the dex/control ratio 
was greater than 2.0 are included in Fig. 2A; other cells in Fig. 2B. The 
cell capacitance of control and treated cells in (A) was 30.2 f 3.9 pF 
(mean f S.E., n = 9) and 30.1 f 3.6 pF (n = 1 l), respectively, and for 
experiments in (B) 32.2 f 3.5 pF (n = 19) and 34.5 f 3.8 pF (n = 23), 
respectively. Currents were elicited by 70 ms step pulses to different 
membrane potentials from a holding potential of -80 mV. Symbols 
are mean !I S.E. of 9 control and 11 treated cells in (A), and 20 control 
and 23 treated cells in (B). There was a significant difference (P < 0.05) 
between control and dexamethasone-treated c lls at -20 to +50 mV 
in (A) by the ANOVA test. (C) Sample currents from a control cell 
(cell fld16, whole cell capacitance 47.1 pF) and a dexamethasone- 
treated cell (cell dld16, 33.5 pF). (D) Expanded view of the currents 
at -20 mV, from (C). The larger current was after treatment with 
dexamethasone. T-current was measured as the difference between 
peak current and the steady-state current at the end of the voltage step 
(dotted lines). 
binding, Hayashi et al. [4,17] concluded that dexa- 
methasone affects calcium entry through L-type Ca” 
channels in A7r5 cells. They further suggested that this 
effect requires the glucocorticoid receptor and protein 
synthesis, since it was blocked by the glucocorticoid 
antagonist RU 38486, cycloheximide, or actinomycin 
D. Thus, dexamethasone might act by increasing the 
synthesis of new calcium channels. In spite of this evi- 
dence, alternative or/and different effects of dexa- 
methasone could not be excluded. For example, gluco- 
corticoids might depolarize the cell membrane, which 
would increase Ca” entry through L-type calcium 
channels, and enhance binding of DHPs [5,7]. Such a 
possibility is not consistent with our results, since all the 
experiments were carried out under voltage clamp con- 
ditions. 
Dexamethasone might also increase calcium currents 
indirectly, by affecting the synthesis of components of 
second messenger pathways that can modulate L-type 
calcium channels. Supporting this speculation is the ef- 
fect of glucocorticoids on several receptors, G-proteins, 
and kinases [17-241. In this respect, a role for protein 
kinase C (PKC) in the stimulatory effect of dexa- 
methasone on L-channels was suggested, as this gluco- 
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Fig. 3. Effects of dexamethasone on calcium channels recorded from 
cell-attached patches. (A) A histogram of the distribution of number 
of channels per patch. (B) Current-voltage relationship for single open 
channels. Each symbol indicates the mean value of openings from one 
patch. The lines were calculated by linear regression analysis. 
corticoid increases the activity of both the cytosolic and 
membrane-bound fractions of PKC [ 171. However, this 
interpretation must be taken with caution, as the effect 
of PKC on calcium channel activity is still controversial 
even under control conditions [5,12,25,26]. 
We approached the investigation of the reported 
modulatory effect of dexamethasone on calcium chan- 
nels using patch clamp techniques. One difficulty is that 
L-type calcium currents in A7r5 cells are intrinsically 
variable, even under control conditions (2-31 pA/pF in 
the present study; see also [5,8]). Equal variability exists 
in the regulation of this current by/?-adrenergic agonists 
[5], vasopressin [5,27], activators of PKC [5,12,25,26], 
and in the voltage-dependent inactivation of the current 
[8,13]. This variability could arise from uncontrolled 
factors in the culture medium, and may reflect the well- 
described phenotypic instability of vascular smooth 
muscle in cell culture. 
In spite of the variability, we found a tendency for 
dexamethasone to increase L-type calcium currents in 
cells that had low current levels under control condi- 
tions. One interesting possibility is that the mechanism 
activated by dexamethasone was already active in prep- 
arations with higher basal current levels. When the in- 
crease in whole cell current was observed, there was no 
effect on the single channel conductance, on the shape 
of the current-voltage relationship, or on inactivation. 
These results argue against an effect of dexamethasone 
on the single-channel current or on the probability that 
a channel is open, since either effect should change the 
shape of the current-voltage relationship. The most nat- 
ural explanation of an increase in p(open) for a voltage- 
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dependent channel is a shift in the activation curve, so 
that channels open at more negative voltages, which 
would shift the peak of the current-voltage curve. It is 
conceivable that p(open) could be increased by the same 
factor at every voltage, but a 2-fold increase in p(open) 
would require that p(open) be less than 0.5 in control 
conditions, even at extreme positive voltages. In con- 
trast, an increase in the number of active channels 
would naturally predict an increase in current at all 
voltages, without effect on the shape of the current- 
voltage relationship, as we observe. We cannot rigor- 
ously rule out an effect on p(open), but our results 
strongly suggest hat dexamethasone acts by increasing 
the number of calcium channels ready to open upon 
depolarization. Interestingly, up-regulation of calcium 
currents by glucocorticoids has been reported recently 
in hippocampal neurons [28]. In contrast to the potenti- 
ating effect of dexamethasone on T-currents in PC12 
cells [29], we found that T-current activity was not af- 
fected in A7r5 cells after treatment with dexamethasone. 
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